|
JP2006265244A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Pfizer Prod Inc |
Ｃｔｌａ４抗体とホルモン治療を用いた前立腺癌の治療
|
|
MX2007011767A
(es)
*
|
2005-03-23 |
2007-10-18 |
Pfizer Prod Inc |
Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
|
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
US9738872B2
(en)
|
2008-10-30 |
2017-08-22 |
Yeda Research And Development Co. Ltd. |
Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
|
|
PT2769737T
(pt)
*
|
2009-07-20 |
2017-06-29 |
Bristol Myers Squibb Co |
Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
|
|
CN102844045A
(zh)
|
2010-02-08 |
2012-12-26 |
艾更斯司股份有限公司 |
结合于161p2f10b蛋白的抗体药物偶联物(adc)
|
|
JP2013540731A
(ja)
*
|
2010-09-08 |
2013-11-07 |
イェダ リサーチ アンド デベロップメント カンパニー リミテッド |
安定かつ長期間の生着のための免疫抑制薬物組合せ
|
|
CN103282047B
(zh)
|
2010-09-08 |
2016-08-24 |
耶达研究及发展有限公司 |
抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
|
|
MX347954B
(es)
|
2010-09-29 |
2017-05-19 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
WO2013035099A1
(en)
|
2011-09-08 |
2013-03-14 |
Yeda Research And Development Co. Ltd. |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
TWI606063B
(zh)
|
2012-08-23 |
2017-11-21 |
艾澤西公司 |
結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
|
|
WO2015017552A1
(en)
|
2013-08-01 |
2015-02-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
EP3256165B1
(en)
*
|
2015-02-13 |
2021-07-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
EP3268038B1
(en)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
EP4679095A3
(en)
|
2015-05-18 |
2026-05-06 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
EP3322424B1
(en)
|
2015-07-16 |
2023-10-11 |
Yeda Research and Development Co., Ltd. |
Use of anti third party central memory t cells
|
|
RU2619208C2
(ru)
*
|
2015-10-08 |
2017-05-12 |
ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс |
Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
DK3551660T5
(da)
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
ES3064681T3
(en)
|
2017-01-18 |
2026-04-28 |
Yeda Res And Development Co Ltd |
Genetically modified veto cells and use of same in immunotherapy
|
|
US10751368B2
(en)
|
2017-01-18 |
2020-08-25 |
Yeda Research And Development Co. Ltd. |
Methods of transplantation and disease treatment
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
CA3073984A1
(en)
|
2017-09-21 |
2019-03-28 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-ctla4 antibodies and uses thereof
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
SG11202005692WA
(en)
|
2017-12-20 |
2020-07-29 |
Harbour Biomed Shanghai Co Ltd |
Antibodies binding ctla-4 and uses thereof
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
WO2019164970A1
(en)
*
|
2018-02-20 |
2019-08-29 |
Emory University |
Hpv proteins, antibodies, and uses in managing abnormal epithelial cell growth
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
WO2021009188A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
|
EP4017542A1
(en)
|
2019-10-04 |
2022-06-29 |
Tae Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
|
CN115997008A
(zh)
|
2020-04-22 |
2023-04-21 |
艾欧凡斯生物治疗公司 |
协调用于患者特异性免疫疗法的细胞的制造的系统和方法
|
|
AR122043A1
(es)
*
|
2020-05-12 |
2022-08-03 |
Bristol Myers Squibb Co |
Dosificación y administración del anticuerpo anti-ctla-4 activable
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
JP2025539816A
(ja)
|
2022-11-21 |
2025-12-09 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
|
|
AU2024304180A1
(en)
|
2023-06-13 |
2026-01-08 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
WO2025034812A2
(en)
|
2023-08-07 |
2025-02-13 |
Tae Life Sciences Llc |
Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof
|
|
WO2025264533A1
(en)
|
2024-06-17 |
2025-12-26 |
Adcentrx Therapeutics Inc. |
Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
|